Results 151 to 160 of about 409,460 (298)
The McCance Brain Care Score and Mortality: Evidence From a Large‐Scale Population‐Based Cohort
ABSTRACT Objectives This study aimed to examine the relationship between the McCance Brain Care Score (BCS) and mortality in the general population. Methods We conducted a prospective, population‐based cohort study using data from the UK Biobank. Participants with complete data enabling calculation of BCS and full mortality information were included ...
Zhiqiang Xu, Xiaoxiao Wang, Nan Li
wiley +1 more source
Audiovisual estimation of Time-to-contact. [PDF]
Leblond S +3 more
europepmc +1 more source
ABSTRACT Objective This study aimed to systematically observe the clinical manifestations, immune cell subsets, and dynamic changes in serological indicators in patients with myasthenia gravis (MG) before and after efgartigimod (EFG) treatment. Methods We analyzed the baseline data, laboratory parameters, and lymphocyte subset proportions in MG ...
Tiancheng Luo +9 more
wiley +1 more source
Links between central visual field loss and movement processing during walking. [PDF]
Shanidze NM +3 more
europepmc +1 more source
Phospholipase C-β1 Directly Accelerates GTP Hydrolysis by Gαq and Acceleration Is Inhibited by Gβγ Subunits [PDF]
Peter Chidiac, Elliott M. Ross
openalex +1 more source
Association of Corticospinal Tract Asymmetry With Ambulatory Ability After Intracerebral Hemorrhage
ABSTRACT Background Ambulatory ability after intracerebral hemorrhage (ICH) is important to patients. We tested whether asymmetry between ipsi‐ and contra‐lesional corticospinal tracts (CSTs) assessed by diffusion tensor imaging (DTI) is associated with post‐ICH ambulation.
Yasmin N. Aziz +25 more
wiley +1 more source
Associations of volatile organic compound exposure with phenotypic age acceleration and the synergistic interaction of dietary micronutrients. [PDF]
Zhang H, Tian W, Qi G, Zhou B, Sun Y.
europepmc +1 more source
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin +11 more
wiley +1 more source
Performance Analysis of 200 m Qualifying Time Trial: Gear Ratios, Velocity Patterns, and Acceleration Strategies. [PDF]
Ikeda Y +3 more
europepmc +1 more source

